HOME > Our Business >List of Partners

RIBOMIC, Inc. is a leading company in the world developing innovative aptamer therapeutics.

List of Partners

Our company has been promoting the pharmaceutical discovery program in collaboration with the following corporate partners.

Collaboration with Corporate Partners

Partner name Alliance content
Otsuka Pharmaceutical Co., Ltd. Collaborative research on pharmaceutical aptamer discovery and development
Zenyaku Kogyo Co., Ltd. Technical advice and contract research on aptamer therapeutics
Taisho Pharmaceutical Co., Ltd. Collaborative research on pharmaceutical aptamer discovery and development

Licensee

Classification Project Target Derivation destination Right Indication
In-house RBM004 NGF
(nerve growth factor)
Fujimoto pharmaceutical Corporation Exclusive worldwide Pain

In April 2014, we entered into the world-wide exclusive license agreement of the anti-NGF aptamer (RBM004) with Fujimoto Pharmaceutical Corporation. We received the contract lump, and receive milestone revenues associated with the development progress, part of the sublicensing payment, and loyalty after product launch in accordance with the sales.

Collaboration with Academic Partners

Partner name Alliance content
The University of Tokyo,
Institute of Medical Science
Joint basic study on RNA aptamer’s potential and application
Nagoya University
Graduate School of Medicine
Joint study on therapeutic anti-midkine aptamer for neuroblastoma tumor in children
Tohoku University,
Graduate School of Pharmaceutical Sciences
Joint study on therapeutic anti-autotaxin aptamer
RIKEN,
Quantitative Biology Center
Joint structure-function study of the aptamer-protein interplay by NMR
The University of Tokyo,
Graduate School of Science
Joint study of X-ray crystallography of autotaxin complexed with anti-autotaxin aptamer